RecruitingMigraineEpisodic MigraineChronic Migraine, Headache
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.
Sponsor: Hospital Universitari Vall d'Hebron Research Institute
You may qualify if…
- ✓ Migraine diagnosis according to ICHD-III.
- ✓ Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations.
- ✓ Signature of informed consent.
You may not qualify if…
- ✕ Presence of headache different from migraine.
- ✕ Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study.
Where it's recruiting
Florida
Miami
Source: ClinicalTrials.gov · NCT07159750 · last updated 2025-09-08